VYNE THERAPEUTICS INC.

(VYNE)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
0.4370 USD   +12.37%
06/17VYNE Therapeutics Completes Enrollment in Trial of Atopic Dermatitis Treatment
MT
06/17VYNE THERAPEUTICS : Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis - Form 8-K
PU
06/17VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

05/18/2022 | 08:01am EDT

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at the HC Wainwright & Co. Global Investment Conference on May 25, 2022. Management will also be available for one-on-one meetings with investors.

HC Wainwright & Co. Global Investment Conference – Presentation Details

Date:Wednesday, May 25, 2022
Time:9:00 a.m. ET
Webcast Link:https://journey.ct.events/view/f49ba6f9-4835-4fb5-9a1c-0c341c71da26
 *a replay will be available on the VYNE website for 90 days, following the presentation

Please contact your HC Wainwright & Co. representative if you would like to schedule a one-on-one meeting during the conference.

For more information about the HC Wainwright & Co. Global Investment Conference, please refer to the conference website.

About VYNE Therapeutics Inc.

VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis, and access to a library of bromodomain & extra-terminal (BET) domain inhibitors licensed from In4Derm Limited. The BET inhibitor platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi) and access to a library of (BET) domain inhibitors for the potential treatment of immuno-inflammatory conditions.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com


Primary Logo

Source: VYNE Therapeutics Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about VYNE THERAPEUTICS INC.
06/17VYNE Therapeutics Completes Enrollment in Trial of Atopic Dermatitis Treatment
MT
06/17VYNE THERAPEUTICS : Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of ..
PU
06/17VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
06/17VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of..
AQ
06/17VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatm..
CI
05/18VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
AQ
05/17VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
05/17TRANSCRIPT : VYNE Therapeutics Inc. - Special Call
CI
05/12VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
05/12Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q1 Loss $-0.14
MT
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 0,43 M - -
Net income 2022 -37,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,75x
Yield 2022 -
Capitalization 25,3 M 25,3 M -
Capi. / Sales 2022 58,5x
Capi. / Sales 2023 101x
Nbr of Employees 28
Free-Float 98,5%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,44 $
Average target price 6,00 $
Spread / Average Target 1 273%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-57.16%25
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-14.90%274 360
ABBVIE INC.13.59%271 782